A comparative study on proteomics between LNCap and DU145 cells by quantitative detection and SELDI analysis

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 28, Issue 2, 2008, Pages 174-178

  Sun, Weigui ^a   Ye, Zhangqun ^a   Mi, Zhenguo ^b   Shi, Tianliang ^b   Han, Cunzhi ^b   Guo, Sutang ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANXI CANCER HOSPITAL   (China)

Author keywords

DU145; LNCap; Prostate cancer; Protein; Quantitative and qualitative study; SELDI TOF MS

Indexed keywords

PROTEIN; TUMOR MARKER;

ARTICLE; CHEMISTRY; COMPARATIVE STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; MALE; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PROSTATE TUMOR; PROTEOMICS; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MASS SPECTROMETRY; PROSTATIC NEOPLASMS; PROTEINS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 43749098060     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-008-0215-5     Document Type: Article

References (15)

1. Kambhampati S, Ray G, Sengupta K et al. Growth factors involved in prostate carcinogenesis. Front Biosci, 2005,1(10):1355-1367
2. Engwegen J Y, Gast M C, Schellens J H et al. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci, 2006,27(5):251-259
3. Roboz J. Mass spectrometry in diagnostic oncoproteomics. Cancer Invest, 2005,23(5):465-478
4. Pan Y Z, Xiao X Y, Zhao D et al. Application of surface-enhanced laser desorption/ionization time-of-flight-based serum proteomic array technique for the early diagnosis of prostate cancer. Asian J Androl, 2006,8(1):45-51
5. Hellström M, Lexander H, Franzén B et al. Proteomics in prostate cancer research. Anal Quant Cytol Histol, 2007, 29(1):32-40
6. Skytt A, Thysell E, Stattin P et al. SELDI-TOF-MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Int J Cancer, 2007,121(3):615-620
7. Semmes O J, Feng Z, Adam B L et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reprocibility. Clin Chem, 2005,51(1):102-112
8. Kohli M, Siegel E, Bhattacharya S et al. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) for deter mining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark, 2006,2(6):249-258
9. Faria P C, Saba K, Neves A F et al. Transforming growth factor-beta 1 gene poly-morphisms and expression in the blood of prostate cancer patients. Cancer Invest, 2007,25(8):726-732
10. Ghosh R, Garcia G E, Crosby K et al. Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia, 2007,9(11):893-899
11. Le L, Chi K, Tyldesley S et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem, 2005,51(4):695-707
12. Malik G, Ward M D, Gupta S K et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res, 2005, 11(3):1073-1085
13. Engwegen J Y, Helgason H H, Cats A et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol, 2006, 12(10): 1536-1544
14. Le L, Chi K, Tyldesley S et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem, 2005, 51(4):695-707
15. Park Y, Downing S R, Kim D et al. Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data. Bioinformatics, 2007, 23(12):1451-1458